



CLAIMS

1. A method of promoting bone formation in an animal simultaneous with callus
5 distraction, comprising administering to an animal in need thereof an effective amount of a
growth hormone or a growth hormone secretagogue.
2. The method of claim 1, wherein the animal is a human being.
- 10 3. The method of claim 1, wherein the growth hormone is human growth hormone.
4. The method of claim 1, wherein the growth hormone secretagogue is selected from
the group consisting of:
5-amino-5-methyl-hex-2-enoic acid N-methyl-N-((1R)-1-(methyl-((1R)-1-
15 (methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(naphthalen-2-yl)ethyl)amide of for-
mula I:




I

H-Aib-His-D-2Nal-D-Phe-Lys-NH₂ of formula II:



and N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethoxy)ethyl]-2-amino-2-methylpropanamide mesylate of formula III:



5. A method of enhancing the healing of bone fractures in an animal subjected to distraction osteogenesis, the method comprising administering, to the animal in need thereof, a growth hormone or a growth hormone secretagogue in an amount sufficient to provide bone formation simultaneous with the distraction procedure.
- 5
6. The method of claim 5, wherein the animal is a human being.
7. The method of claim 5, wherein the growth hormone is human growth hormone.
- 10 8. The method of claim 5, wherein the growth hormone secretagogue is selected from the group consisting of:
- 5-amino-5-methyl-hex-2-enoic acid N-methyl-N-((1R)-1-(methyl-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(naphthalen-2-yl)ethyl)amide (formula I);
- 15 H-Aib-His-D-2Nal-D-Phe-Lys-NH₂ (formula II); and
- N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylethyloxy)ethyl]-2-amino-2-methylpropanamide mesylate (formula III).
9. A method of treating patients suffering from fractured bones, and post-traumatic and idiopathic deformities of extremities by distraction osteogenesis, comprising administering an effective amount of a growth hormone or a growth hormone secretagogue to a patient in need of such a treatment in conjunction with the distraction procedure.
- 20
10. The method of claim 9, wherein the patient is a human being.
- 25
11. The method of claim 9, wherein the growth hormone is human growth hormone.
12. The method of claim 9, wherein the growth hormone secretagogue is selected from the group consisting of:
- 30 5-amino-5-methyl-hex-2-enoic acid N-methyl-N-((1R)-1-(methyl-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(naphthalen-2-yl)ethyl)amide (formula I);
- H-Aib-His-D-2Nal-D-Phe-Lys-NH₂ (formula II); and
- 35 N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylethyloxy)ethyl]-2-amino-2-methylpropanamide mesylate (formula III).